What amount sold does Banyan Biomarkers, Inc. report in Form D filings?

The latest linked filings report $23.9M sold across 5 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Banyan Biomarkers, Inc.'s most recent SEC filing?

Banyan Biomarkers, Inc.'s most recent Form D filing was on 2020-06-18.

How many investors does Banyan Biomarkers, Inc. have?

The most recent Form D filing lists 8 investor(s).

What type of securities does Banyan Biomarkers, Inc. offer?

Banyan Biomarkers, Inc.'s SEC Form D filings indicate debt offerings.

Banyan Biomarkers, Inc.

CIK: 0001581877·Biotechnology·SAN DIEGO, CA·Corporation

Reported Sold

$23,888,977

Total Filings

Identified Offerings

Last Filed

Jun 18, 2020

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jun 18, 2020Form D — New notice

Reported sold: $2,265,419 · Target: $2,965,419

Rule 506(b)·8 investors

Jan 4, 2019Form D — New notice

Reported sold: $2,225,847 · Target: $5,000,000

Rule 506(b)·13 investors

Feb 7, 2017Form D/A — Amendment

Reported sold: $11,397,714 · Target: $12,000,000

Rule 506(b)·16 investors

Changed: Reported amount sold, Offering target, Reported investors

Sep 27, 2016Form D/A — Amendment

Reported sold: $3,073,146 · Target: $10,000,000

Rule 506(b)·13 investors

Changed: Reported amount sold, Offering target, Reported investors

Mar 18, 2015Form D — New notice

Reported sold: $1,808,145 · Target: $5,000,000

Rule 506(b)·8 investors

Feb 25, 2014Form D — New notice

Reported sold: $1,999,999 · Target: $1,999,999

Rule 506(b)·6 investors

Jul 31, 2013Form D — New notice

Reported sold: $5,999,998 · Target: $5,999,998

Rule 506·17 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

29%

Latest reported sold across 5 identified offerings

$23,888,977

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Henry Nordhoff

Related Person

Appears on 5 filings

Steven Richieri

Related Person

Appears on 5 filings

Stanford Warshawsky

Related Person

Appears on 5 filings

William Roper, Jr.

Related Person

Appears on 5 filings

Julie Pashkowsky

Related Person

Appears on 4 filings

Tony Grover

Related Person

Appears on 4 filings

Andrew von Eschenbach, M.D.

Related Person

Appears on 3 filings

Ronald Hayes, Ph.D.

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jun 18, 2020	New	$2,965,419	$2,265,419	8
Jan 4, 2019	New	$5,000,000	$2,225,847	13
Feb 7, 2017	Amendment	$12,000,000	$11,397,714	16
Sep 27, 2016	Amendment	$10,000,000	$3,073,146	13
Mar 18, 2015	New	$5,000,000	$1,808,145	8
Feb 25, 2014	New	$1,999,999	$1,999,999	6
Jul 31, 2013	New	$5,999,998	$5,999,998	17

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Theravie Pharma, Inc.

Biotechnology

Offering target: $2,250,000

Filed Oct 19, 2026